Alnylam Pharmaceuticals reported insider activity from Melissa McLaughlin, the company's Chief Human Resources Officer, who sold a combined 3,902 shares of common stock across two dates in early April 2026. The total proceeds from these transactions amounted to $1.27 million.
On April 2, McLaughlin disposed of 1,615 shares through a series of transactions with executed prices spanning from $316.61 to $325.49, generating cumulative proceeds of $519,014. The company states these sales were carried out to satisfy minimum statutory tax withholding obligations.
Four days later, on April 6, McLaughlin sold an additional 2,287 shares at prices ranging between $320.14 and $333.94, producing $755,328 in proceeds. Those April 6 transactions were executed under a pre-arranged Rule 10b5-1(c) trading plan that McLaughlin adopted on December 16, 2025.
Following the two sets of transactions, McLaughlin directly holds 9,443 shares of Alnylam common stock.
These insider sales come while Alnylam, a biotech company with a stated valuation of $42.3 billion, was trading near $319.47 per share. The company has reported robust top-line momentum, with revenue growth of 65% over the trailing twelve months. Despite that operational growth, InvestingPro analysis cited in company commentary flags ALNY as trading above its Fair Value, placing it among the most overvalued names in that assessment framework.
Valuation metrics cited include a PEG ratio of 0.67, which the analysis notes as indicative of attractive growth prospects. Analysts are forecasting earnings of $9.65 per share for 2026, according to the data presented. For investors seeking further analysis, ALNY's Pro Research Report is available on InvestingPro as one of the platform's suite of reports.
In corporate developments related to its pipeline, Alnylam presented data from its cardiovascular portfolio at the American College of Cardiology's Annual Scientific Session. The company shared analyses from the HELIOS-B study of vutrisiran, a treatment for transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM), with an emphasis on quality-of-life measures and treatment adherence.
Equity analysts have maintained varied views and targets on Alnylam following product-launch commentary and clinical updates. H.C. Wainwright reiterated a Buy rating with a $510 price target after an investor webinar highlighting AMVUTTRA's first-year performance post-approval. Stifel kept a Buy rating with a $444 target, expressing confidence in the product's launch trajectory. BofA Securities maintained a Buy rating and a $460 target, noting the expansion of the ATTR-CM patient population estimate. Morgan Stanley retained an Equalweight rating with a $360 target and acknowledged Alnylam's positioning in the face of potential competition from Ionis Pharmaceuticals and AstraZeneca.
Investors and market participants will likely weigh the insider sale alongside the company's reported revenue growth, differing analyst price targets, and InvestingPro's Fair Value assessment when forming views on ALNY's near-term market prospects.